The 2026 European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain. As one of the most influential academic events in the global hematology field, the application of allo-HSCT in myeloid neoplasms remains a focus of academic debate and innovation. This specialized session, chaired by Professor Anna Sureda (Catalan Institute of Oncology, Barcelona, Spain), focused on post-transplant molecular monitoring, refinement of prognostic strategies, and algorithm optimization for refractory cases in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Research teams from China, Switzerland, Sweden, Spain, and other countries shared five milestone academic reports, providing new evidence-based medical grounds for clinical precision transplantation.

At the 2026 European Hematology Association (EHA) Annual Meeting, experts including Professor Paolo Ghia from Università Vita-Salute San Raffaele, Professor Barbara Eichhorst from the University Hospital of Cologne, and Professor Elżbieta Kalicińska from Wroclaw Medical University jointly released and interpreted the latest version of the "EHA Guidelines for the Management of Chronic Lymphocytic Leukemia (CLL) and Richter Transformation (RT)". This update not only incorporates data from multiple cutting-edge targeted studies but also includes "Richter Transformation" in the title for the first time, aiming to provide a more practical clinical pathway for hematologists worldwide.

At the 2026 European Hematology Association (EHA) Annual Congress, Professor Claire Harrison from Guy's and St Thomas' NHS Foundation Trust, London, shared the latest research data on the mutation-specific monoclonal antibody INCA033989 (hereinafter referred to as "989") for the treatment of calreticulin (CALR)-mutated myelofibrosis (MF) patients. This study aims to evaluate the safety, tolerability, and preliminary efficacy of this first-in-class drug in monotherapy and combination regimens, providing a new path for precision treatment in this specific subpopulation of CALR-mutated patients.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Giuseppe De Franceschi from the University of Verona, Italy, representing the joint working group of the European Society for Blood and Marrow Transplantation (EBMT) and EHA, delivered an in-depth interpretation of the latest update to the "Guidelines for Patient Selection for Gene Therapy in Transfusion-Dependent β-Thalassemia (TDT)." This guideline update aims to integrate the latest clinical evidence from gene addition and gene editing technologies to provide standardized patient screening and follow-up pathways for hematologists worldwide.

At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Georg Lenz from the University of Münster, Germany, on behalf of the FRONTMIND study group, delivered an oral presentation on the final analysis results of the Phase 3 FRONTMIND study. This study aimed to investigate the efficacy and safety of adding the CD19 monoclonal antibody Tafasitamab and the immunomodulatory drug Lenalidomide to the standard R-CHOP regimen (hereafter referred to as Tafa-Len+R-CHOP) for the frontline treatment of patients with high-risk diffuse large B-cell lymphoma (DLBCL).

At the 2026 European Hematology Association (EHA) Annual Meeting, the association presented the "EHA Research Excellence Award" to Professor George Vassiliou from the University of Cambridge and the Wellcome Sanger Institute, in recognition of his pioneering contributions to the fields of biology, pathogenesis, and early intervention in myeloid malignancies. In the subsequent award lecture, Professor Vassiliou reviewed the landmark research conducted by his team over the past 15 years regarding the identification of driver genes in acute myeloid leukemia (AML), the evolutionary logic of clonal hematopoiesis (CH), and the development of clinical prediction tools.